SGEN — Seagen Share News
0.000.00%
Last trade - 00:00HealthcareBalancedLarge Cap
- $43.15bn
- $41.92bn
- $1.96bn
Pfizer shares sink after it resets 2024 COVID expectations (updated)
Pfizer forecasts 2024 revenue below Wall Street expectations (updated)
Pfizer's 2024 revenue forecast below Wall Street estimate
U.S. STOCKS ON THE MOVE-Expedia, Moderna, HubSpot
Antitrust legendarily unpredictable despite Epic
U.S. STOCKS ON THE MOVE-C4 Therapeutics, Eagle Bulk, SilverBow Resources
U.S. STOCKS ON THE MOVE-Wyndham Hotels, Alphabet, Candel Therapeutics
Seagen rises as Pfizer gets approval for $43 bln buyout
Pfizer gets OK for $43-bln Seagen deal after donating cancer drug rights (updated)
Brief: Pfizer To Complete The Acquisition Of Seagen After Receiving Regulatory Approvals
Pfizer says received approvals to close Seagen deal
Brief: Seagen Says Adcetris Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival At 12 Months In Phase 2 Trial Of Patients
Brief: TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
Brief: Astellas Pharma Inc - FDA Grants Priority Review For Sbla Of Padcev With Keytruda For First-Line Treatment Of Advanced Bladder Cancer
Arbitrator Issues Final Award, Ordering Seagen To Pay Daiichi Sankyo Arbitration Costs And Attorneys' Fees
Sankyo Appeals Amended Texas Court Judgement In Patent Dispute With Seagen
Seagen Inc reports results for the quarter ended in September - Earnings Summary
Brief: Seagen Inc - Decided To Stop Further Development Of Sea-Tgt, Sgn-Alpv And Sgn-Stnv
Brief: Seagen Q3 EPS USD -1.15